We report a case of immunotherapy associated myopericarditis in a patient treated with Nivolumab/Ipilimumab. We furthermore performed a comprehensive literature review regarding the biological mechanisms of cancer immunity, the pathophysiology behind immunotherapy related adverse effects (irAEs), current guideline, and the role of immune checkpoint inhibitors to the recurrent irAEs.